Results 251 to 260 of about 507,211 (287)

Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution? [PDF]

J Pharmacokinet Pharmacodyn
Gülave B, Lesmana A, de Lange EC, van Hasselt JGC.   +3 more
europepmc   +1 more source

Measurement of cyclosporin induced changes in P-glycoprotein function at the human blood-brain barrier using [¹⁸F]MC225 and PET. [PDF]

Eur J Nucl Med Mol Imaging
Mossel P, Salvi de Souza G, Willemsen ATM, Stormezand GN, Colabufo NA, Toyohara J, Boersma HH, Dierckx RAJO, Lammertsma AA, Bartels AL, Luurtsema G.   +10 more
europepmc   +1 more source

Glycoprotein P pharmacogenetic assessment role in digoxin pharmacotherapy individualization: a new approach for an old problem

, 2006
D. A. Sychev, I. V. Ignatiev, Д. А. Андреев, Л. Г. Пошукаева, Pavel Kolkhir, Э.В. Жукова, V. G. Kukes   +6 more
openalex   +1 more source

Spice components as modulating agents of P-glycoprotein - An in silico study.

Indian J Pharmacol
Mukhopadhyay S, Roy C, Ghosh P.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

P-glycoprotein homologues

1994
Multidrug resistance (MDR) is defined by the simultaneous acquisition of cellular resistance to a broad range of cytotoxic compounds bearing little or no structural and functional homologies [1–5]. MDR is caused in cultured cells in vitro [6–9] and in tumor cells in vivo [10–12] by the overexpression of P-glycoprotein (Pgp) (reviewed in [13]).
E, Buschman, P, Lepage, P, Gros
openaire   +2 more sources